Clinical Trial Update: Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the rabies virus neutralizing activity and safety of CL184, a monoclonal antibody cocktail, for simulated rabies post-exposure prophyla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rabies

Drugs mentioned

• CL184 (CL184)

Snippet

Sponsor: Crucell Holland BV | Conditions: Rabies | Phase 2 | Status: COMPLETED